Agilent Technologies is expected to report Q2 2026 revenue of $1.71 billion and earnings per share of $1.40, with the stock currently trading at $162.45 against an average analyst target of $178.50.
The primary focus for investors this quarter is the recovery trajectory of the Life Sciences and Applied Markets Group (LSAG) revenue.
Market participants are searching for evidence of rebounding demand in China and a pickup in biopharma capital equipment spending after several quarters of cautious budgeting. Continued growth in the high-margin CrossLab services segment remains a critical offset to volatility in the core instrument business.